Evidence map›Paper›PMID 28447909›Full record

ArticleNanomedicine (London, England)2017

Cholic acid-based novel micellar nanoplatform for delivering FDA-approved taxanes.

Gaurav Bharadwaj, Viet Nhan, ShanChao Yang, Xiaocen Li, Anand Narayanan, Ana Carolina Macarenco, Yu Shi, Darrion Yang, Letícia Salvador Vieira, Wenwu Xiao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Gaurav BharadwajDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Viet NhanDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
ShanChao YangDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Xiaocen LiDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Anand NarayananDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Ana Carolina MacarencoDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Yu ShiDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Darrion YangDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Letícia Salvador VieiraDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Wenwu XiaoDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Yuanpei LiDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Kit S LamDepartment of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
University of California, Davis · USUC Davis Comprehensive Cancer CenterTianjin Institute of Pharmaceutical Research (China) · CNUniversidade de São Paulo · BR

Funding

Therapeutic Targeting Agents for Ovarian CancerR01CA115483 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI LAM, KIT S · 2005 to 2019
$5.5M
The rodent eye as a non-invasive window for understanding cancer nanotherapeuticsU01CA198880 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LAM, KIT S · 2015 to 2019
$2.9M
Stimuli-responsive crosslinked theranostics against advanced prostate cancerR01CA199668 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LI, YUANPEI · 2015 to 2019
$1.8M
NCI NIH HHS R01 CA115483NCI NIH HHS R01 CA199668NCI NIH HHS U01 CA198880
6 · The paper itself

Abstract

aimTo structurally modify our existing cholic acid (CA)-based telodendrimer (TD; PEG MATERIALS &

methodsGeneration of hybrid TDs was achieved by replacing four of the eight CAs with biocompatible organic moieties using solution-phase peptide synthesis. Drug loading was done using the standard evaporation method.

resultsHybrid TDs can generate micelles with narrow size distributions, low critical micelle concentration values (1-6 μM), better hematocompatibility and lack of in vitro cytotoxicity.

conclusionAlong with PEG

Indexed as

MicellesAntineoplastic AgentsBridged-Ring CompoundsCell Line, TumorCholic AcidDocetaxelDrug CarriersHumansNanoparticlesNeoplasmsPaclitaxelTaxoidsAntineoplastic AgentsBridged-Ring CompoundsCholic AcidDocetaxelDrug CarriersMicellesPaclitaxeltaxaneTaxoidscabazitaxelcholic aciddocetaxeldrug deliverymicellenanoparticlepaclitaxeltaxanetelodendrimer

Identifiers

PMID28447909
PMCPMC5480805
OpenAlexW2608221633

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.